The U.S. Food and Drug Administration (FDA) has posted a notice regarding a nationwide dietary supplement recall involving a product found to contain an undeclared Tadalafil. On January 28, 2026, Akkarco LLC of Lorton, Virginia, voluntarily recalled Ashfiat Alharamain Energy Support after FDA testing confirmed the presence of tadalafil, which is a prescription drug approved for the treatment of male erectile dysfunction.
Tadalafil belongs to a class of drugs known as phosphodiesterase (PDE-5) inhibitors and is not permitted in dietary supplements. The product was marketed as a honey-based energy support supplement and distributed nationwide in the United States, including through third-party e-commerce marketplaces such as Amazon. The recalled product is packaged in a glass bottle with an orange label and carries the following identifying information:
Product Name: Ashfiat Alharamain Energy Support
UPC: 1234561870003
Batch No.: ENCOT24
Expiration Date: October 2028
Tadalafil is approved by the FDA only for use under medical supervision. Products containing undeclared tadalafil may pose serious health risks, particularly for individuals with heart disease, high or low blood pressure, or those taking nitrates or other medications. Potential adverse effects may include cardiovascular complications, blood pressure changes, dizziness, headaches, and related symptoms.
The recall was initiated after Akkarco LLC was notified by the FDA of laboratory findings and an FDA online alert confirming the presence of the undeclared drug ingredient. As of the announcement date, no confirmed adverse events have been reported in connection with the recalled product.
Consumers who have purchased Ashfiat Alharamain Energy Support should stop using the product immediately and follow return or disposal instructions provided by the seller or distributor. Consumers with questions may contact United Legal Experts at office@unitedlegalexperts.com, Monday through Friday, 8:00 a.m. to 4:00 p.m. EST. Adverse reactions or quality issues can be reported to the FDA’s MedWatch Adverse Event Reporting Program online or by mail or fax.
According to the company’s risk statement, exposure to meloxicam at doses exceeding the recommended maximum daily dose of 15 mg per day may result in serious and potentially life-threatening events, including blood clots, heart attack, and stroke. Dangerous drug interactions may also occur in individuals taking blood thinners or other NSAIDs. As of the announcement date, 123Herbals reported no known adverse events related to the product.
Consumers are advised to stop using the recalled product and return it to the place of purchase, discard it, or consult a healthcare provider. Customers who purchased Silintan through the company’s website may return the product by mail for a refund. The company is notifying distributors and customers by email and has provided contact information for consumer questions.
FDA photos of recalled supplements.
